Antiviral therapy in acute viral hepatitis B: Why and when

0Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Acute viral hepatitis B is cleared in more than 95% of patients, while the remainder ones may develop either chronic HBV infection or, rarely, fulminant hepatitis. Therefore there are elderly patients with severe acute HBV hepatitis caractherized by high serum bilirubin levels >15 mmole/dl, international normalized ratio (INR) with value more than 1.6; these patients are caractherized by a severe outcome of HBV infection. As known, outcome of infection and the pathogenesis of liver diseases are determined by viral and host factors, such as T reg lymphocytes. T regs may be associated with a negative immune response such as an inhibition of gamma- IFN secretion. The impact of viral load on antiviral T cell responses may play a critical role in thaese patients, influencing disease persistence and immune response. Antiviral drugs could be useful in these patients determing a possible down -regulation of T regs.

Cite

CITATION STYLE

APA

Morelli, G., Perrella, A., Sbreglia, C., Bellopede, P., Riccio, V., & Perrella, O. (2009). Antiviral therapy in acute viral hepatitis B: Why and when. Infectious Agents and Cancer, 4(1). https://doi.org/10.1186/1750-9378-4-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free